Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 4 | Cellular & Molecular Biology Letters

Fig. 4

From: CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation

Fig. 4

CLDN6 modulates the localization of palmitoylated RAS via VPS4A. A-D The localization of RAS (red) in BC cells with CLDN6 overexpression(A), palmitic acid treatment (B), SREBP1 overexpression (C), and 2BP treatment (D-E). Scale bar, 20 μm. F The interaction between VPS4A and HRAS. G, H The impact of CLDN6 overexpression on palmitoylation (G) and localization (H) of HRAS (green) in BC cells. Scale bar, 20 μm. I, J The regulatory impact of CLDN6 overexpression on the binding between HRAS and VPS4A (I) and the colocalization of HRAS (red) and VPS4A (green) (J). Scale bar, 20 μm. K-L The alteration of the binding between HRAS and VPS4A (K) and the colocalization of HRAS (red) with VPS4A (green) (L) in SREBP1-overexpressing BC cells induced by 2BP treatment. Scale bar, 20 μm

Back to article page